Licensing additional

The electrowinning process developed by Ginatta (34) has been purchased by M.A. Industries (Atlanta, Georgia), and the process is available for licensing (qv). MA Industries have also developed a process to upgrade the polypropylene chips from the battery breaking operation to pellets for use by the plastics industry. Additionally, East Penn (Lyons Station, Pennsylvania), has developed a solvent-extraction process to purify the spent acid from lead—acid batteries and use the purified acid in battery production (35). 

Are new environmental, health and safety permits, authorizations or licenses needed prior to producing the material If yes, explain what additional permits or authorizations are needed and how long they will take to secure. 

According to 10 CFR 50,73, the holder of an operating license for a nuclear power plant (the licensee) must submit an LER for a reportable event, within 30 days after discovery. An event b reportable regardless of the plant mode, power level, structure, system, or component that initiated the event. In addition the licensee must report the completion of any nuclear plant shutdown required by the plant s Technical Specifications or any operation or condition prohibited by the plant s Technical Specifications, or any deviation from the plant s Technical Specifications. LERs are available on the Internet at http //www.nrc.gov/NRR/DAILY/97mmdddr.htm, where inrn is the... 

The Oil Pollution Act, wliich prohibits the discluirge of oil from any vessel into navigable waters, was passed in 1924. The penalties for violators were the same is those for the Refuse Act of 1899 with one addition tlie Coast Guard had the authority to suspend or revoke licenses held by the officers of vessels found to be in viohition of the act. 

From these results, the Institut Fran ais du Petrole (IFF) has developed a biphasic version of its established monophasic Dimersol process , which is offered for licensing under the name Difasol process [98]. The Difasol process uses slightly acidic chloroaluminate ionic liquids with small amounts of allcylaluminiums as the solvent for the catalytic nickel center. In comparison to the established Dimersol process , the new biphasic ionic liquid process drastically reduces the consumption of Ni-cata-lyst and allcylaluminiums. Additional advantages arise from the good performance obtained with highly diluted feedstodcs and the significantly improved dimer selectivity of the Difasol process (for more detailed information see Section 5.3). 

In addition to the NRTI lamivudine (3TC) and the NtRTI adefovir dipivoxU and tenofovir disoproxil fumarate (which has been recently licensed for the treatment of chronic hepatitis B), two other nucleoside analogues, that is, entecavir and L-dT (tel-bivudine) (Fig.4aa), have been licensed for the treatment of HBV infections. Two other compounds 3 -Val-L-dC (valtorcitabine) and L-FMAU (clevudine) (Fig. 4aa) are in clinical development for the treatment of HBV infections, and yet two other compounds, that is, racivir and elvucitabine (Fig. 3), yield potential for the treatment of both HBV and HIV infections. 

In the near future new drugs for the treatment of Alzheimer s disease are expected to be licensed, and it would be extremely valuable to be able to compare them in a clear and well-defined framework. In addition, if economic evaluation is to inform health and social care providers and policy-makers about the potential impact of new interventions in practice, estimation of the value for money of these new interventions requires consideration of (a) the perceived and objective risks and benefits of care (b) attitudes of people with... 

Approximately 30% to 40% of currently licensed drugs are targeted at GPCRs and thus represent a highly significant source of income for many pharmaceutical companies (80). In the specific context of chemokine receptors, it is clear that they are involved in a number of prominent pathologies and thus represent an important therapeutic target (81). For example, chemokines and their receptors lie at the center of all immune and inflammatory disorders and are responsible for the aberrant accumulation of leukocytes at inflamed sites in autoimmune conditions. In addition, over the past 12 years, it has become clear... 

In addition, nuclear utilities in the United States are also extending plant operating lives. Baltimore Gas and Electric is seeking an extension of the license for its Calvert Cliffs facility -the news out of the NRC is favorable - and Duke Power has submitted an application for the license renewal of its Oconee plant. Extension of the licenses of such economically-competitive plants can make an important contribution to meeting our environmental goals. 

In the last twenty odd years, almost all nuclear endeavors in the U.S. have run into bureaucratic and litigious delays, making their schedules and costs unpredictable. In addition to reactor construction, there are the bureaucratic delays in the waste repository programs. Another example is the attempt to build a new uranium enrichment plant in the state of Louisiana, a plant which uses advanced technology demonstrated in several countries in Europe. Licensing started over seven years ago and is still held up by issues without relevance to technology or safety. It is approaching the point where the delays, and costs may lead to the abandonment of a potential asset... 

Two companies are in the process of renewing their operating licenses at five reactors with the Nuclear Regulatory Commission for an additional 20 years of operation. We expect the NRC to approve the first of those requests—BaltimorSas and Electric s application for its two-unit Calvert Cliffs Nuclear Power Plan—neMarch. 

In short, we expect that most nuclear power reactors will be renewing their licenses eventually. Clearly, owners of these nuclear units believe that operating for an additional 20 years is a good business decision. 

---